facebook twitter linkedin
  • images/stories/slider.png
  • images/stories/slider2.png
  • images/stories/slider3.png
  • images/stories/slider4.png

NEWS RELEASES

  • H3 Biomedicine and Selvita Reach First Research Milestone in Precision Cancer Medicines Collaboration

    Cambridge, MA and Krakow, Poland, 22 May 2014 — H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies in Eas…

    Read More...

  • Selvita continues to improve financial results in Q1 2014

    Krakow, 13 May 2014 - Selvita, a drug discovery company listed on Warsaw Stock Exchange NewConnect market reported PLN0.57m net earnings in Q1 2014, compared to PLN1.0 m net loss in Q1 2013. This is the second quarter in a row that Selvita finished w…

    Read More...

  • Selvita will present new data from its PIM/FLT3 and MNK1/2 oncology programs during AACR Annual Meeting 2014

    Krakow, Poland, 11 March 2014 – Selvita, the largest independent drug discovery company in Central and Eastern Europe, will present new data at poster sessions at AACR Annual Meeting 2014, which will take place on April 5 - 9, 2014 at San Diego Conve…

    Read More...